HuniLife Biotechnology, Inc.

HLB has in-licensed the novel ENO1 technology from NHRI and DCB. NHRI signed up for the competition for Technology Transfer Award at the 2018 Taipei Biotech. The technology transfer of ENO1 stands out in the fierce competition and won the Gold Medal. The ENO1 technology was initially co-developed by NHRI and DCB. It is a plasminogen receptor and has a unique Mechanism of Action (MOA). Experiments had demonstrated that anti-ENO1 antibodies can effectively block the function of ENO1 expressed on the surface of cancer cells and inflammatory immune cells, and hence, can inhibit the cancer growth and activation of inflammation. Since ENO1 has a unique MOA, therefore, the anti-ENO1 antibody (HuL001) will be the first-in-class drug in the drug market. HLB will complete all pre-clinical studies and enter the Phase I clinical trial in 2019Q2.

HuniLihe is awarded in 2017 with a research grant of Taiwan government A+ program for preclinical development of HuL001 in multiple sclerosis. The aim of this government’s A+ Program is to encourage and guide businesses to invest in high value-adding cutting-edge industrial technologies and to help biotech company get involved in innovation, development, and research programs. It is a highly prestigious award and a symbol of recognition to our innovative technologies.

“We are thrilled to have the opportunity to collaborate with Shimadzu Corporation in developing novel cancer drugs for medical care”, said Dr. Ying-Jye Wu, Chairman and CEO of HuniLife. “This collaboration has created an excellent synergy by employing the expertise in drug development of HuniLife and the proprietary Lactosome technology of Shimadzu Corporation. We strongly believe that Lactosome technology in drug development will enhance the drug efficacy and reduce toxicity in treating patients. We are looking forward to a productive and prosperous collaboration”.

Multiple sclerosis (MS) is a chronic disabling immune disease occurred in the central nervous system. In MS patients, the immune system attacks the myelin sheath of nerve fibers and causes the nerves to deteriorate becoming permanently damaged. The symptoms of MS vary widely and can affect many parts of the body. The main symptoms of MS include fatigue, difficulty in walking, muscle stiffness and spasms, problems with balance and move co-ordination. Currently, there is no cure for multiple sclerosis. MS can be divided into four categories based on clinical criteria: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), and progressive-relapsing MS (PRMS).